IPO registrations (S-1, F-1) · Registrants

Accelerate Diagnostics, Inc

SEC CIK
727207 · filings on EDGAR ↗
Former names
ACCELR8 TECHNOLOGY CORP (1995–2012)
Registration
Form S-1, first filed 2023-12-13, last 2024-01-18; 1 initial registration, 2 amendments
Outcome
Final prospectus filed 2024-01-23; declared effective 2024-01-19
Industry (SIC)
Laboratory Analytical Instruments 3826
Incorporated in
DE
Business address
3950 S. COUNTRY CLUB ROAD #470, BUILDING 3-307, Tucson, AZ 85714
EIN
84-1072256
EDGAR entity type
operating
Insiders and CEO pay
Accelerate Diagnostics, Inc on the corporate pages

Offering terms

Final price
$1.73 per share (424B1 filed 2024-01-23)
Shares sold
5,515,767
Gross proceeds
$9,542,276 before underwriting discounts and any over-allotment option
Listing
Nasdaq under the symbol AXDX
Lead underwriters
William Blair
Syndicate
Craig-Hallum; September 30, Year Ended December 31 (2,023); Gross profit (loss) (1,917); As of December 31 (2,023)

Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.

Filings 5

FiledFormWhat it isName as filedEDGAR
2023-12-13S-1S-1 (registration)Accelerate Diagnostics, Inc0001104659-23-125787 ↗
2024-01-16S-1/AS-1/A (amendment)Accelerate Diagnostics, Inc0001104659-24-003888 ↗
2024-01-18S-1/AS-1/A (amendment)Accelerate Diagnostics, Inc0001104659-24-004669 ↗
2024-01-19EFFECTEFFECT (declared effective)Accelerate Diagnostics, Inc9999999995-24-000159 ↗
2024-01-23424B1424B1 (final prospectus)Accelerate Diagnostics, Inc0001104659-24-005673 ↗

Prospectus pages read 2

FiledFormRead asRangePriceSharesProceedsListingUnderwritersWhat was foundDocument
2024-01-18S-1/Aregistration statement4,500,000-Nasdaq AXDX2primary document; shares headline, cover names 2document ↗
2024-01-23424B1final prospectus$1.735,515,767$9,542,276Nasdaq AXDX5primary document; price line, shares headline, proceeds computed, underwriting table 3, cover names 2document ↗

Officers, directors and large holders Forms 3, 4 and 5

InsiderRoleTitleFilingsYearsOn this site
GEIMER THOMAS JDirector,OfficerCEO and CFO; CEO/CFO; Chief Executive Officer/CFO92007–2012
GERRETSON CHARLES EDirector82008–2012
Kucera John D.Director72009–2012
Howson DavidOfficerPresident42009–2012
PATIENCE JOHNDirector; Director,TenPercentOwner; TenPercentOwner372012–2024
SCHULER JACK WDirector,TenPercentOwner1912012–2024
ABEJA VENTURES, LLCTenPercentOwner32012–2013
Mehren LawrenceDirector,Officer; Director,Officer,TenPercentOwnerCEO; PRESIDENT AND CEO132012–2019
Strobeck MatthewDirector272012–2024
REICHLING STEVENOfficerCFO; Chief Financial Officer; CHIEF FINANCIAL OFFICER322012–2023
FEINBERG LARRY NTenPercentOwner252013–2016
TEN BRINK FRANK JMDirector132013–2023
MILLER MARK CDirector162013–2023
Bantock PeteOfficerCHIEF COMMERCIAL OFFICER; See Remarks52013–2017
Martin JoanOfficerEXECUTIVE VP AND HEAD OF EMEA12017
Price RonOfficerHead of Commercial Operations; See Remarks; SVP & HEAD OF COM OPS AMERICAS102017–2022
Brown Thomas DDirector132017–2023
Watts Charles MDirector82017–2023
HUMPHRIES ROMNEYOfficerChief Scientific Officer; CHIEF SCIENTIFIC OFFICER32019–2020
Phillips JackDirector,Officer; OfficerChief Executive Officer; CHIEF OPERATING OFFICER; PRESIDENT AND CEO452019–2025
DIGGELMANN ROLAND DDirector32019–2020
FRANCESCONI LOUISEDirector122019–2024
SAFWAT NEDALOfficerChief Strategy Officer22020
MASSARANY HANYDirector122021–2024
BURRIS WAYNEDirector72022–2024
Mertz Larry MichaelOfficerChief Technology Officer132022–2025
Patience DavidOfficerChief Financial Officer202023–2025
Black Mark S.Director32023–2024
Ogilvie Marran H.Director32023–2024
Regan JenniferDirector42023–2024
Shalhoub Paul VincentDirector12025
NATHAN GILBERT EDirector12025

Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.

Private offerings before or after (Form D)

First filedIssuerIndustryOfferingSoldInvestorsFilings
2022-04-07Accelerate Diagnostics, IncBiotechnology$4,000,000$4,000,00031
2021-09-29Accelerate Diagnostics, IncBiotechnology$30,450,000$30,450,00031
2021-03-01Accelerate Diagnostics, IncBiotechnology$1,550,000$1,550,00052
2019-08-28Accelerate Diagnostics, IncBiotechnology$999,992$999,99211
2014-06-04Accelerate Diagnostics, IncBiotechnology$19,499,609$19,499,60941

Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.

Also on this site Fuzzy

RecordName as filedWhereDatasetMatched by
Business registrationAccelerate Diagnostics INCAZState business registriesname and state
Federal award recipientACCELERATE DIAGNOSTICS, INCAZFederal spending (USAspending)name and state
Form D issuerAccelerate Diagnostics, IncAZForm D private offeringsCIK (EXACT)
Lobbying clientACCELERATE DIAGNOSTICS, INC.AZFederal lobbying (LDA)name and state
Paying companyAccelerate Diagnostics Inc.AZOpen Payments (drug and device company payments)name and state
Patent assigneeAccelerate Diagnostics, Inc.AZPatents (USPTO)name and state
SEC filerAccelerate Diagnostics, IncSEC filers (EDGAR)CIK (EXACT)
Trademark ownerAccelerate Diagnostics, Inc.AZTrademarks (USPTO)name and state
Form 5500 plan sponsorACCELERATE DIAGNOSTICS, INC.EIN (EXACT)

Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.

Others with the same interests

SIC industry Laboratory Analytical Instruments, AZ first:

More with this interest.

In other datasets, the same topic (Technology) in AZ:

Interests: Laboratory Analytical Instruments · Technology